Activities of daily living - Outcome during two years in galantamine treated Alzheimer patients

Wattmo, Carina; Wallin, Åsa; Minthon, Lennart

Published in:

2007

Document Version:
Publisher’s PDF, also known as Version of record

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
**Objective**

To analyse and present the outcome of longitudinal change in ADL function and cognition in patients treated with galantamine for two years.

**Methods and Subjects**

The Swedish Alzheimer Treatment Study (SATS) is an open, long-term, multicentre study in a routine clinical setting. Patients with the diagnosis of Alzheimer’s Disease received the cholinesterase inhibitor galantamine. The 122 patients were assessed with several functional and cognitive rating scales including IADL, PSMS, FAST, MMSE and ADAS-cog at baseline and every 6 months for a total period of two years.

The expected rate of IADL decline in untreated patients has been calculated using a linear equation as presented by Green et al.[1, 2]:

$$\Delta IADL = 10,124 – 0,332 \times \text{IADL}_{\text{Baseline}}$$

in which $\Delta IADL$ is the annual rate of decline of IADL and IADL$_{\text{Baseline}}$ is the IADL score at baseline.

A two-step cluster analysis was performed to reveal any natural groupings (clusters) of the patients based on the ADL scores at baseline.

**Results**

**Fig A** PSMS and FAST

After two years of galantamine treatment the total mean change from baseline in PSMS score was 4,3 ± 4,9 (mean ± SD) points. Using the mathematical model by Green et al.[1] patients in this study are expected to decline approximately 11,7 ± 3,3 points on IADL score after 2 years. The IADL changes from baseline show a strong linear relationship (0,000<p<0,01) with cognition at the 18 and 24 months assessments.

**Fig B** IADL

110 patients with complete items in the three ADL scales at baseline were analysed in a two-step cluster analysis. Two clusters (groups) were identified (p<0,000).

**Fig C**

The significant variables between the two groups, in order of significance, were:
- **FAST 3 Decreased job functioning; difficulty in travelling**
- **PSMS 10 Higher PSMS; difficulty in communication**
- **PSMS 11 Higher PSMS; difficulty in understanding**
- **PSMS 4 Higher PSMS; difficulty in eating**
- **PSMS 3 Higher PSMS; difficulty in communication**

**Conclusions**

The instrumental ADL scale in the galantamine treated patients showed a faster decline of function than the PSMS and FAST scales, but significantly less than expected by using the mathematical model by Green et al.

Increasing strength in the linear correlation between the three ADL scales as well as cognition was observed during the two years of the study.

Cluster analysis based on ADL scores at baseline, identified two subgroups: with different cognitive ability, dissimilar proportion of apoE4-carriers and rate of change in basic functional decline.

**Baseline characteristics**

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Number of patients (n)</th>
<th>Gender (males/females)</th>
<th>Galantamine mean dose mg/day</th>
<th>2 year completion rate</th>
<th>Age at investigation</th>
<th>Duration, years</th>
<th>MMSE</th>
<th>ADAS-cog*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients (n)</td>
<td>122</td>
<td>39 % / 61 %</td>
<td>15.5 - 19.4</td>
<td>78 %</td>
<td>72.4 ± 7.7</td>
<td>3.0 ± 2.0</td>
<td>23.2 ± 4.2</td>
<td>17.2 ± 8.4</td>
</tr>
<tr>
<td>Gender (males/females)</td>
<td>122</td>
<td>39 % / 61 %</td>
<td>15.5 - 19.4</td>
<td>78 %</td>
<td>72.4 ± 7.7</td>
<td>3.0 ± 2.0</td>
<td>23.2 ± 4.2</td>
<td>17.2 ± 8.4</td>
</tr>
<tr>
<td>Galantamine mean dose mg/day</td>
<td>15.5 - 19.4</td>
<td>78 %</td>
<td>72.4 ± 7.7</td>
<td>3.0 ± 2.0</td>
<td>23.2 ± 4.2</td>
<td>17.2 ± 8.4</td>
<td>13.7 ± 5.1</td>
<td>7.0 ± 2.1</td>
</tr>
<tr>
<td>2 year completion rate</td>
<td>78 %</td>
<td>72.4 ± 7.7</td>
<td>3.0 ± 2.0</td>
<td>23.2 ± 4.2</td>
<td>17.2 ± 8.4</td>
<td>13.7 ± 5.1</td>
<td>7.0 ± 2.1</td>
<td></td>
</tr>
<tr>
<td>Age at investigation*</td>
<td>72.4 ± 7.7</td>
<td>3.0 ± 2.0</td>
<td>23.2 ± 4.2</td>
<td>17.2 ± 8.4</td>
<td>13.7 ± 5.1</td>
<td>7.0 ± 2.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration, years*</td>
<td>72.4 ± 7.7</td>
<td>3.0 ± 2.0</td>
<td>23.2 ± 4.2</td>
<td>17.2 ± 8.4</td>
<td>13.7 ± 5.1</td>
<td>7.0 ± 2.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMSE*</td>
<td>72.4 ± 7.7</td>
<td>3.0 ± 2.0</td>
<td>23.2 ± 4.2</td>
<td>17.2 ± 8.4</td>
<td>13.7 ± 5.1</td>
<td>7.0 ± 2.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADAS-cog*</td>
<td>72.4 ± 7.7</td>
<td>3.0 ± 2.0</td>
<td>23.2 ± 4.2</td>
<td>17.2 ± 8.4</td>
<td>13.7 ± 5.1</td>
<td>7.0 ± 2.1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The patients in cluster 1 are more cognitive impaired at baseline than the other group and have lower percentage of apoE4-carriers. No significant differences in gender, duration, age at investigation or mean dose of galantamine during the study was observed. The cluster 1 patients also decline significantly faster in the long-term outcome of PSMS score compared to the other group; IADL and FAST scales do not show this difference.

**References**
